BEDFORD, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Insulet Corporation (Nasdaq: PODD - News), the manufacturer and marketer of the OmniPod® Insulin Management System, announced today that it has filed a registration statement relating to an underwritten public offering of 4,898,398 shares of its common stock, all of which are being sold by selling stockholders. Insulet has granted the underwriters the right to purchase up to an additional 734,759 shares to cover over-allotments, if any. Insulet will not receive any proceeds from the sale of shares by the selling stockholders.
